Update on Wegener granulomatosis.
Wegener granulomatosis classically involves clinical disease of the upper airways, lungs, and kidneys. Ninety percent of patients present with symptoms involving the upper or lower airways, or both, and it should be suspected in any patient with pulmonary hemorrhage, glomerulonephritis, mononeuritis multiplex, unexplained multisystem disease, or progressive unresponsive sinus disease. Current treatments induce remission and allow long-term survival.
Langford
Carol A
CA
Center for Vasculitis Care and Research, Department of Rheumatic and Immunologic Diseases, The Cleveland Clinic Foundation, OH 44195, USA.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D003520:Cyclophosphamide / Q000627:therapeutic use; D003937:Diagnosis, Differential; D000068800:Etanercept; D014890:Granulomatosis with Polyangiitis / Q000175:diagnosis* / Q000188:drug therapy*; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D011241:Prednisone / Q000627:therapeutic use; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000069283:Rituximab; D003520:Cyclophosphamide; D000069285:Infliximab; D000068800:Etanercept; D011241:Prednisone